Financhill
Sell
40

FBIO Quote, Financials, Valuation and Earnings

Last price:
$1.77
Seasonality move :
-3.66%
Day range:
$1.66 - $1.78
52-week range:
$1.36 - $2.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.34x
P/B ratio:
2.28x
Volume:
411.8K
Avg. volume:
350.2K
1-year change:
-9.56%
Market cap:
$48.3M
Revenue:
$84.5M
EPS (TTM):
-$13.27

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
FBIO
Fortress Biotech
$16.3M -$0.75 -9.13% -41.51% $15.33
ARVN
Arvinas
$62.8M -$0.96 71.95% -5.19% $45.26
CKPT
Checkpoint Therapeutics
-- -$0.02 -100% -69.7% $4.33
DERM
Journey Medical
$14.2M -- -4.5% -- $10.00
HEPA
Hepion Pharmaceuticals
-- -- -- -- --
MBIO
Mustang Bio
-- -$8.00 -- -89.43% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
FBIO
Fortress Biotech
$1.75 $15.33 $48.3M -- $0.00 0% 0.34x
ARVN
Arvinas
$8.70 $45.26 $598.3M -- $0.00 0% 2.37x
CKPT
Checkpoint Therapeutics
$3.99 $4.33 $220.5M -- $0.00 0% --
DERM
Journey Medical
$5.31 $10.00 $110.9M -- $0.00 0% 1.83x
HEPA
Hepion Pharmaceuticals
$0.02 -- $4.4K -- $0.00 0% --
MBIO
Mustang Bio
$1.42 -- $3.7M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
FBIO
Fortress Biotech
71.75% 0.988 900.37% 0.99x
ARVN
Arvinas
0.11% 1.554 0.05% 4.58x
CKPT
Checkpoint Therapeutics
-- 4.013 -- 0.23x
DERM
Journey Medical
64.42% 1.772 16.89% 0.99x
HEPA
Hepion Pharmaceuticals
-- 2.743 -- --
MBIO
Mustang Bio
-- 5.297 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
FBIO
Fortress Biotech
$9.3M -$22.1M -94.06% -- -166.72% -$20.1M
ARVN
Arvinas
-- -$58.2M -32.92% -32.96% -98.31% -$84.4M
CKPT
Checkpoint Therapeutics
-- -$9.7M -- -- -16275.61% -$11.2M
DERM
Journey Medical
$9.3M -$2.9M -64.68% -125.77% -11.16% -$1.2M
HEPA
Hepion Pharmaceuticals
-- -$4.5M -- -- -- -$2.5M
MBIO
Mustang Bio
-- -$1.5M -- -- -- -$1.8M

Fortress Biotech vs. Competitors

  • Which has Higher Returns FBIO or ARVN?

    Arvinas has a net margin of -87.96% compared to Fortress Biotech's net margin of -76.18%. Fortress Biotech's return on equity of -- beat Arvinas's return on equity of -32.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    FBIO
    Fortress Biotech
    63.87% -$0.76 $41M
    ARVN
    Arvinas
    -- -$0.63 $562.3M
  • What do Analysts Say About FBIO or ARVN?

    Fortress Biotech has a consensus price target of $15.33, signalling upside risk potential of 776.19%. On the other hand Arvinas has an analysts' consensus of $45.26 which suggests that it could grow by 420.27%. Given that Fortress Biotech has higher upside potential than Arvinas, analysts believe Fortress Biotech is more attractive than Arvinas.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBIO
    Fortress Biotech
    1 0 0
    ARVN
    Arvinas
    13 5 0
  • Is FBIO or ARVN More Risky?

    Fortress Biotech has a beta of 1.750, which suggesting that the stock is 74.992% more volatile than S&P 500. In comparison Arvinas has a beta of 1.954, suggesting its more volatile than the S&P 500 by 95.435%.

  • Which is a Better Dividend Stock FBIO or ARVN?

    Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -14.46% of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBIO or ARVN?

    Fortress Biotech quarterly revenues are $14.6M, which are smaller than Arvinas quarterly revenues of $59.2M. Fortress Biotech's net income of -$12.9M is higher than Arvinas's net income of -$45.1M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.34x versus 2.37x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBIO
    Fortress Biotech
    0.34x -- $14.6M -$12.9M
    ARVN
    Arvinas
    2.37x -- $59.2M -$45.1M
  • Which has Higher Returns FBIO or CKPT?

    Checkpoint Therapeutics has a net margin of -87.96% compared to Fortress Biotech's net margin of -16268.29%. Fortress Biotech's return on equity of -- beat Checkpoint Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    FBIO
    Fortress Biotech
    63.87% -$0.76 $41M
    CKPT
    Checkpoint Therapeutics
    -- -$0.23 -$15.7M
  • What do Analysts Say About FBIO or CKPT?

    Fortress Biotech has a consensus price target of $15.33, signalling upside risk potential of 776.19%. On the other hand Checkpoint Therapeutics has an analysts' consensus of $4.33 which suggests that it could grow by 8.61%. Given that Fortress Biotech has higher upside potential than Checkpoint Therapeutics, analysts believe Fortress Biotech is more attractive than Checkpoint Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBIO
    Fortress Biotech
    1 0 0
    CKPT
    Checkpoint Therapeutics
    1 2 0
  • Is FBIO or CKPT More Risky?

    Fortress Biotech has a beta of 1.750, which suggesting that the stock is 74.992% more volatile than S&P 500. In comparison Checkpoint Therapeutics has a beta of 1.412, suggesting its more volatile than the S&P 500 by 41.242%.

  • Which is a Better Dividend Stock FBIO or CKPT?

    Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Checkpoint Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -14.46% of its earnings as a dividend. Checkpoint Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBIO or CKPT?

    Fortress Biotech quarterly revenues are $14.6M, which are larger than Checkpoint Therapeutics quarterly revenues of $41K. Fortress Biotech's net income of -$12.9M is lower than Checkpoint Therapeutics's net income of -$9.7M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Checkpoint Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.34x versus -- for Checkpoint Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBIO
    Fortress Biotech
    0.34x -- $14.6M -$12.9M
    CKPT
    Checkpoint Therapeutics
    -- -- $41K -$9.7M
  • Which has Higher Returns FBIO or DERM?

    Journey Medical has a net margin of -87.96% compared to Fortress Biotech's net margin of -16.34%. Fortress Biotech's return on equity of -- beat Journey Medical's return on equity of -125.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    FBIO
    Fortress Biotech
    63.87% -$0.76 $41M
    DERM
    Journey Medical
    63.87% -$0.12 $30.7M
  • What do Analysts Say About FBIO or DERM?

    Fortress Biotech has a consensus price target of $15.33, signalling upside risk potential of 776.19%. On the other hand Journey Medical has an analysts' consensus of $10.00 which suggests that it could grow by 88.32%. Given that Fortress Biotech has higher upside potential than Journey Medical, analysts believe Fortress Biotech is more attractive than Journey Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBIO
    Fortress Biotech
    1 0 0
    DERM
    Journey Medical
    3 0 0
  • Is FBIO or DERM More Risky?

    Fortress Biotech has a beta of 1.750, which suggesting that the stock is 74.992% more volatile than S&P 500. In comparison Journey Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock FBIO or DERM?

    Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Journey Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -14.46% of its earnings as a dividend. Journey Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBIO or DERM?

    Fortress Biotech quarterly revenues are $14.6M, which are smaller than Journey Medical quarterly revenues of $14.6M. Fortress Biotech's net income of -$12.9M is lower than Journey Medical's net income of -$2.4M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Journey Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.34x versus 1.83x for Journey Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBIO
    Fortress Biotech
    0.34x -- $14.6M -$12.9M
    DERM
    Journey Medical
    1.83x -- $14.6M -$2.4M
  • Which has Higher Returns FBIO or HEPA?

    Hepion Pharmaceuticals has a net margin of -87.96% compared to Fortress Biotech's net margin of --. Fortress Biotech's return on equity of -- beat Hepion Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    FBIO
    Fortress Biotech
    63.87% -$0.76 $41M
    HEPA
    Hepion Pharmaceuticals
    -- -$0.72 --
  • What do Analysts Say About FBIO or HEPA?

    Fortress Biotech has a consensus price target of $15.33, signalling upside risk potential of 776.19%. On the other hand Hepion Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 7211438.46%. Given that Hepion Pharmaceuticals has higher upside potential than Fortress Biotech, analysts believe Hepion Pharmaceuticals is more attractive than Fortress Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBIO
    Fortress Biotech
    1 0 0
    HEPA
    Hepion Pharmaceuticals
    0 0 0
  • Is FBIO or HEPA More Risky?

    Fortress Biotech has a beta of 1.750, which suggesting that the stock is 74.992% more volatile than S&P 500. In comparison Hepion Pharmaceuticals has a beta of 1.625, suggesting its more volatile than the S&P 500 by 62.537%.

  • Which is a Better Dividend Stock FBIO or HEPA?

    Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hepion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -14.46% of its earnings as a dividend. Hepion Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBIO or HEPA?

    Fortress Biotech quarterly revenues are $14.6M, which are larger than Hepion Pharmaceuticals quarterly revenues of --. Fortress Biotech's net income of -$12.9M is lower than Hepion Pharmaceuticals's net income of -$4.9M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Hepion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.34x versus -- for Hepion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBIO
    Fortress Biotech
    0.34x -- $14.6M -$12.9M
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$4.9M
  • Which has Higher Returns FBIO or MBIO?

    Mustang Bio has a net margin of -87.96% compared to Fortress Biotech's net margin of --. Fortress Biotech's return on equity of -- beat Mustang Bio's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    FBIO
    Fortress Biotech
    63.87% -$0.76 $41M
    MBIO
    Mustang Bio
    -- -$0.04 --
  • What do Analysts Say About FBIO or MBIO?

    Fortress Biotech has a consensus price target of $15.33, signalling upside risk potential of 776.19%. On the other hand Mustang Bio has an analysts' consensus of -- which suggests that it could grow by 6942.25%. Given that Mustang Bio has higher upside potential than Fortress Biotech, analysts believe Mustang Bio is more attractive than Fortress Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    FBIO
    Fortress Biotech
    1 0 0
    MBIO
    Mustang Bio
    0 0 0
  • Is FBIO or MBIO More Risky?

    Fortress Biotech has a beta of 1.750, which suggesting that the stock is 74.992% more volatile than S&P 500. In comparison Mustang Bio has a beta of 1.817, suggesting its more volatile than the S&P 500 by 81.737%.

  • Which is a Better Dividend Stock FBIO or MBIO?

    Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mustang Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -14.46% of its earnings as a dividend. Mustang Bio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FBIO or MBIO?

    Fortress Biotech quarterly revenues are $14.6M, which are larger than Mustang Bio quarterly revenues of --. Fortress Biotech's net income of -$12.9M is lower than Mustang Bio's net income of -$1.4M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Mustang Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.34x versus -- for Mustang Bio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FBIO
    Fortress Biotech
    0.34x -- $14.6M -$12.9M
    MBIO
    Mustang Bio
    -- -- -- -$1.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
48
SMTC alert for Mar 18

Semtech [SMTC] is down 1.29% over the past day.

Buy
67
PLPC alert for Mar 18

Preformed Line Products [PLPC] is up 0.96% over the past day.

Buy
58
NUTX alert for Mar 18

Nutex Health [NUTX] is down 3.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock